007570 — Ilyang Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Market Cap
KR₩224bn
Enterprise Value
KR₩324bn
Revenue
KR₩269bn

Annual income statement for Ilyang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	343,329	371,348	383,811	266,669	268,861
Cost of Revenue
Gross Profit	181,709	204,403	216,028	116,493	111,475
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	311,175	330,030	343,429	266,750	257,858
Operating Profit	32,154	41,318	40,382	-80.8	11,003
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	28,393	38,927	41,331	-1,799	12,277
Provision for Income Taxes
Net Income After Taxes	21,545	25,956	31,741	-2,030	10,508
Minority Interest
Net Income Before Extraordinary Items
Net Income	10,880	14,384	19,238	-2,409	10,257
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	10,880	14,384	19,238	-2,365	10,013
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	673	780	1,062	463	557
Dividends per Share